REGN Regeneron Pharmaceuticals, Inc. Stock Quote

REGN [NASD]

Index	S&P 500	P/E	14.21	EPS (ttm)	35.35	Insider Own	1.40%	Shs Outstand	105.40M	Perf Week	2.81%
Market Cap	53.72B	Forward P/E	12.48	EPS next Y	40.24	Insider Trans	-0.69%	Shs Float	101.80M	Perf Month	5.72%
Income	4.00B	PEG	1.42	EPS next Q	16.38	Inst Own	88.60%	Short Float	2.70%	Perf Quarter	1.50%
Sales	9.20B	P/S	5.84	EPS this Y	65.30%	Inst Trans	0.43%	Short Ratio	2.92	Perf Half Y	-14.69%
Book/sh	113.63	P/B	4.42	EPS next Y	-11.53%	ROA	24.50%	Target Price	633.82	Perf Year	-10.84%
Cash/sh	32.76	P/C	15.33	EPS next 5Y	10.00%	ROE	38.00%	52W Range	441.00 - 664.64	Perf YTD	3.98%
Dividend	-	P/FCF	26.48	EPS past 5Y	40.80%	ROI	23.90%	52W High	-24.69%	Beta	0.19
Dividend %	-	Quick Ratio	2.60	Sales past 5Y	15.70%	Gross Margin	86.80%	52W Low	13.50%	ATR	11.64
Employees	9123	Current Ratio	3.10	Sales Q/Q	38.30%	Oper. Margin	43.40%	RSI (14)	57.26	Volatility	2.81% 2.29%
Optionable	Yes	Debt/Eq	0.23	EPS Q/Q	86.00%	Profit Margin	43.50%	Rel Volume	0.72	Prev Close	502.34
Shortable	Yes	LT Debt/Eq	0.17	Earnings	May 06 BMO	Payout	0.00%	Avg Volume	941.60K	Price	500.52
Recom	2.00	SMA20	1.67%	SMA50	4.28%	SMA200	-5.66%	Volume	650,541	Change	-0.36%

Jan-25-21

Upgrade

BMO Capital Markets

Market Perform → Outperform

$630

Jan-13-21

Upgrade

The Benchmark Company

Hold → Buy

$590

Jan-08-21

Upgrade

Citigroup

Neutral → Buy

$635 → $575

Oct-05-20

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$690

Aug-20-20

Downgrade

The Benchmark Company

Buy → Hold

Jul-09-20

Upgrade

SunTrust

Hold → Buy

$400 → $750

May-26-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$559 → $734

Apr-28-20

Downgrade

Citigroup

Buy → Neutral

$540 → $575

Apr-17-20

Upgrade

The Benchmark Company

Hold → Buy

$655

Apr-08-20

Initiated

The Benchmark Company

Hold

Mar-31-20

Initiated

Wolfe Research

Peer Perform

Feb-27-20

Initiated

Barclays

Overweight

$530

Feb-26-20

Upgrade

Canaccord Genuity

Hold → Buy

$550

Feb-26-20

Downgrade

Robert W. Baird

Outperform → Neutral

$410

Feb-25-20

Upgrade

Jefferies

Hold → Buy

$355 → $492

Feb-11-20

Upgrade

Argus

Hold → Buy

$430

Dec-24-19

Initiated

Raymond James

Mkt Perform

Dec-16-19

Downgrade

Evercore ISI

Outperform → In-line

Dec-13-19

Upgrade

Credit Suisse

Neutral → Outperform

$400

Nov-12-19

Initiated

SunTrust

Hold

$360

May-11-21 02:09PM	COVID-19 booster shot is likely and its okay: Doctor Yahoo Finance Video
May-10-21 03:06PM	Was The Smart Money Right About Regeneron Pharmaceuticals (REGN)? Insider Monkey
01:53PM	COVID-19 is not at the point yet where we can have mass gatherings: Doctor Yahoo Finance Video
May-07-21 02:04PM	We are not out of the woods with this pandemic: Doctor Yahoo Finance Video
01:54PM	Pfizer begins process of seeking full U.S. vaccine approval: RPT Yahoo Finance Video
09:29AM	Company News for May 7, 2021 Zacks
May-06-21 04:38PM	Regeneron Pops After Covid Treatment Beats First-Quarter Views Investor's Business Daily
04:22PM	US STOCKS-Dow ends at record high after upbeat jobless claims report Reuters
04:00PM	US STOCKS-Dow closes at record high after upbeat jobless claims report Reuters
03:30PM	Regeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call Transcript Motley Fool
01:54PM	U.S. backing waiver of patent protection for vaccines is a complex issue: Doctor Yahoo Finance Video
01:20PM	Regeneron (REGN) Q1 Earnings Beat on Strong Eylea & Dupixent Zacks
12:48PM	US STOCKS-Dow hits record high as cyclicals rise on jobless claims data Reuters
10:47AM	Why Regeneron's Q1 Results Looked Great Despite Its Revenue Miss Motley Fool
10:20AM	US STOCKS-Nasdaq, S&P 500 slip as COVID-19 vaccine makers fall Reuters
09:10AM	Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue Benzinga
09:09AM	US STOCKS-Futures flat after jobless claims data; drugmakers extend fall Reuters
07:45AM	Regeneron (REGN) Tops Q1 Earnings Estimates Zacks
07:34AM	Regeneron Earnings Lift Stock. Heres Why. Barrons.com
06:44AM	UPDATE 3-Regeneron expects continuing demand for its COVID-19 therapy Reuters
06:43AM	Regeneron stock rises, as profit, revenue and sales of SARS-CoV-2 antibody cocktail beat expectations MarketWatch
06:39AM	Regeneron expects continuing demand for its COVID-19 therapy Reuters
06:30AM	Regeneron Reports First Quarter 2021 Financial and Operating Results PR Newswire
06:30AM	Regeneron Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-05-21 02:06PM	Former Acting CDC Director on why it's 'really important' to pay attention to COVID-19 variants Yahoo Finance Video
10:01AM	Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical Zacks
09:19AM	India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail Benzinga
09:01AM	UPDATE 1-India approves Roche/Regeneron antibody cocktail to treat COVID-19 Reuters
08:44AM	Should You Buy Regeneron (REGN) Ahead of Earnings? Zacks
May-04-21 02:02PM	Returning to normal doesnt have to be the goal amid COVID-19 recovery: Doctor Yahoo Finance Video
May-03-21 02:32PM	A one size fits all policy for reopening travel is very concerning: Doctor Yahoo Finance Video
12:00PM	Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings? Zacks
08:00AM	ATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV (casirivimab with imdevimab) and Dupixent® (dupilumab) PR Newswire
07:34AM	Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study Benzinga
Apr-30-21 01:37PM	California has lowest COVID-19 case rate in the U.S.: RPT Yahoo Finance Video
Apr-29-21 05:50PM	Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know Zacks
05:02PM	Regeneron (REGN) Earnings Expected to Grow: Should You Buy? Zacks
01:51PM	NYC reopening timeline is a disastrous issue: Doctor Yahoo Finance Video
Apr-28-21 01:32PM	Its good to lift COVID-19 restrictions right now: UAB Epidemiologist Yahoo Finance Video
01:27PM	Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran Benzinga
06:00AM	Buy Alert: Regeneron Stock Is Headed Higher Motley Fool
Apr-27-21 01:58PM	CDCs latest guidance on outdoor mask wearing is a big milestone: Doctor Yahoo Finance Video
Apr-26-21 01:31PM	The Johnson & Johnson vaccine has become critically important: Doctor Yahoo Finance Video
Apr-24-21 06:00AM	3 Top Coronavirus Stocks to Buy Right Now Motley Fool
Apr-23-21 05:50PM	Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know Zacks
04:05PM	Regeneron Announces Investor Conference Presentations PR Newswire
02:59PM	Moderna Is More Than Its Covid Vaccine. Why Its Time to Buy the Stock. Barrons.com
09:59AM	New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years PR Newswire
Apr-22-21 01:24PM	Vaccine trials on pregnant women show reassuring results: Doctor Yahoo Finance Video
12:10PM	Why Regeneron (REGN) Could Beat Earnings Estimates Again Zacks
Apr-21-21 05:39PM	Regeneron and 4 More Biopharma Stocks That Look Cheap Barrons.com
02:58PM	Im confident in the J&J vaccine and its effectiveness: NewYork Presbyterian CEO Yahoo Finance Video
06:25AM	3 Cheap Cathie Wood Stocks to Buy Right Now Motley Fool
06:10AM	Will Regeneron's COVID Cocktail Win Be Short-Lived? Motley Fool
Apr-20-21 02:15PM	Pandemic eviction bans found to protect entire communities from COVID-19: Study Yahoo Finance Video
Apr-19-21 01:49PM	Doctor on J&J vaccine: You have a much higher risk of getting a blood clot if you smoke Yahoo Finance Video
04:30AM	Market Recap With Jim Cramer: Coinbase and Cathie Wood TheStreet.com
Apr-17-21 07:00AM	3 Cathie Wood Stocks You Can Buy at a Bargain Right Now Motley Fool
06:00AM	Could Vir Biotechnology Be a Millionaire Maker Stock? Motley Fool
Apr-16-21 01:53PM	Vaccinating kids will be very important in getting to herd immunity: Expert Yahoo Finance Video
09:23AM	Pfizer CEO says a third vaccine dose is likely, Moderna updates booster shot timeline Yahoo Finance Video
06:04AM	4 Cathie Wood Stocks That Could Deliver Bigger Gains Than Tesla Motley Fool
Apr-15-21 03:13PM	More domestic medical supply manufacturing is critical for the U.S. : Premier President Yahoo Finance Video
02:04PM	FDA, CDC precaution with vaccine side effects is encouraging: Doctor Yahoo Finance Video
08:18AM	Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More Zacks
Apr-14-21 02:11PM	Vaccine transparency is the best course of action: Doctor Yahoo Finance Video
01:43PM	U.S. in unique position to force increased accountability at the WHO: FDD Yahoo Finance Video
11:34AM	UPDATE 1-Swiss gov't looks to boost domestic COVID-19 vaccine, therapy production Reuters
11:02AM	Moderna is committed to keep chasing new COVID variants: CEO Yahoo Finance Video
10:10AM	Here's How I'd Treat Regeneron TheStreet.com
04:00AM	'Mad Money' Lightning Round: Regeneron, Bumble, Plug Power TheStreet.com
Apr-13-21 02:09PM	Doctor on J&J vaccine pause: CDC is letting the public know they are taking any side effect seriously Yahoo Finance Video
09:28AM	FDA, CDC recommend pause in Johnson & Johnson COVID-19 vaccine Yahoo Finance Video
05:35AM	Vaccine Stocks Checkup: Johnson & Johnson COVID-19 Vaccine Paused TheStreet.com
Apr-12-21 01:51PM	Id still trust vaccines to suppress emergence of more variants: Doctor Yahoo Finance Video
12:53PM	COVID-19 cases keep surging in some U.S. states, and Michigan governor continues plea for more vaccines as shots in arms hits daily record MarketWatch
11:21AM	Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail Zacks
08:33AM	Regenerons Covid-19 Antibody Protects Household Contacts From Infection Barrons.com
08:31AM	Regenerons REGEN-COV Shown To Reduce COVID-19 Progression In Phase 3 Trial SmarterAnalyst
07:47AM	Regeneron says its COVID-19 antibody therapy cut risk of infection progression MarketWatch
06:11AM	UPDATE 2-Regeneron to seek U.S. OK for COVID-19 cocktail to be used for prevention Reuters
05:33AM	Regeneron COVID-19 Cocktail Shows Promise as Preventative Treatment TheStreet.com
01:15AM	Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19 PR Newswire
01:00AM	Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV (casirivimab with imdevimab) PR Newswire
Apr-11-21 08:00PM	Regenerons Covid drug reduces risk of symptomatic illness, study finds Financial Times
11:43AM	4 Undervalued Stocks To Watch For In April Benzinga
Apr-09-21 01:39PM	Pfizers vaccine EUA expansion request is extremely welcomed: Doctor Yahoo Finance Video
08:43AM	NIH recommends Lilly and Regeneron's combination antibody treatments to people with mild and moderate COVID-19 MarketWatch
08:15AM	NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression PR Newswire
Apr-08-21 03:23PM	Study shows wearables could detect COVID-19 earlier Yahoo Finance Video
01:23PM	COVID-19 vaccinations are extraordinarily safe: Doctor Yahoo Finance Video
Apr-07-21 01:26PM	COVID-19 mitigation is the most effective weapon to avoid fourth wave: Doctor Yahoo Finance Video
11:01AM	White House wont support vaccine passports: Psaki Yahoo Finance Video
09:14AM	Regeneron Pharmaceuticals (NASDAQ:REGN) Seems To Use Debt Rather Sparingly Simply Wall St.
06:01AM	3 Top Biotech Stocks to Buy in April Motley Fool
Apr-06-21 04:05PM	Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021 PR Newswire
01:29PM	Theres increasing confidence vaccine supply can meet demand: Doctor Yahoo Finance Video
06:01AM	3 Stocks Cathie Wood Is Selling That Long-Term Investors Should Be Buying Motley Fool
Apr-05-21 02:06PM	Travel boom poses threat to COVID-19 recovery: Doctor Yahoo Finance Video
01:58PM	10 Best Biotech Stocks To Buy For 2021 Insider Monkey

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McCourt Marion	EVP Commercial	May 07	Option Exercise	342.93	1,000	342,930	18,038	May 10 04:02 PM
McCourt Marion	EVP Commercial	May 07	Sale	495.63	1,000	495,630	17,038	May 10 04:02 PM
VAGELOS P ROY	Director	Feb 23	Option Exercise	52.03	250,000	13,007,500	487,088	Feb 24 04:02 PM
RYAN ARTHUR F	Director	Feb 01	Sale	506.92	100	50,692	23,691	Feb 02 04:06 PM
BROWN MICHAEL S	Director	Jan 25	Option Exercise	380.95	2,480	944,756	3,371	Jan 27 04:06 PM
BROWN MICHAEL S	Director	Jan 25	Sale	554.32	2,480	1,374,714	891	Jan 27 04:06 PM
RYAN ARTHUR F	Director	Jan 04	Sale	483.60	100	48,360	23,543	Jan 05 04:09 PM
YANCOPOULOS GEORGE	President and Chief Scientific	Dec 30	Option Exercise	52.03	398,079	20,712,050	908,303	Dec 31 05:30 PM
RYAN ARTHUR F	Director	Dec 01	Sale	520.48	100	52,048	23,643	Dec 02 04:09 PM
MURPHY ANDREW J	EVP Research	Nov 17	Sale	542.73	6,628	3,597,188	47,136	Nov 18 04:02 PM
MURPHY ANDREW J	EVP Research	Nov 16	Option Exercise	30.63	13,736	420,734	60,872	Nov 18 04:02 PM
COLES N ANTHONY	Director	Nov 13	Option Exercise	345.47	11	3,800	654	Nov 13 05:57 PM
RYAN ARTHUR F	Director	Nov 02	Sale	548.54	100	54,854	23,743	Nov 03 05:22 PM
MURPHY ANDREW J	EVP Research	Oct 22	Option Exercise	38.56	5,185	199,926	47,136	Oct 23 04:02 PM
McCourt Marion	SVP Commercial	Oct 05	Option Exercise	342.93	1,000	342,930	14,963	Oct 06 04:07 PM
GOLDSTEIN JOSEPH L	Director	Oct 05	Option Exercise	520.01	9,212	4,790,332	14,855	Oct 06 04:09 PM
McCourt Marion	SVP Commercial	Oct 05	Sale	600.00	1,000	600,000	13,963	Oct 06 04:07 PM
GOLDSTEIN JOSEPH L	Director	Oct 05	Sale	600.00	9,212	5,527,200	5,643	Oct 06 04:09 PM
RYAN ARTHUR F	Director	Oct 01	Sale	558.13	100	55,813	28,343	Oct 05 04:13 PM
BROWN MICHAEL S	Director	Sep 22	Option Exercise	378.77	5,090	1,927,917	5,733	Sep 23 04:01 PM
BROWN MICHAEL S	Director	Sep 22	Sale	552.36	1,000	552,360	9,349	Sep 23 04:01 PM
BROWN MICHAEL S	Director	Sep 22	Sale	552.36	5,090	2,811,512	643	Sep 23 04:01 PM
GOLDSTEIN JOSEPH L	Director	Sep 22	Sale	552.36	20	11,047	5,643	Sep 23 04:00 PM
GOLDSTEIN JOSEPH L	Director	Sep 21	Option Exercise	376.76	16,574	6,244,372	22,217	Sep 23 04:00 PM
GOLDSTEIN JOSEPH L	Director	Sep 21	Sale	549.86	16,554	9,102,446	5,663	Sep 23 04:00 PM
RYAN ARTHUR F	Director	Sep 01	Sale	604.58	100	60,458	28,443	Sep 03 04:18 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Aug 31	Sale	615.04	4,672	2,873,467	14,438	Aug 31 04:37 PM
SING GEORGE L	Director	Aug 31	Sale	612.06	10,000	6,120,555	54,415	Aug 31 04:36 PM
POON CHRISTINE A	Director	Aug 28	Option Exercise	28.44	40,000	1,137,550	41,433	Aug 31 04:35 PM
POON CHRISTINE A	Director	Aug 28	Sale	601.22	40,000	24,048,715	1,433	Aug 31 04:35 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	Aug 27	Option Exercise	52.03	10,000	520,300	21,241	Aug 31 04:37 PM
SING GEORGE L	Director	Aug 25	Option Exercise	273.67	12,750	3,489,292	97,165	Aug 27 04:23 PM
Van Plew Daniel P	EVP & General Mgr Industrial O	Aug 25	Sale	610.89	27,109	16,560,738	20,001	Aug 27 04:21 PM
SING GEORGE L	Director	Aug 25	Sale	612.00	1,000	612,000	3,700	Aug 27 04:23 PM
SING GEORGE L	Director	Aug 25	Sale	607.28	32,750	19,888,518	64,415	Aug 27 04:23 PM
SING GEORGE L	Director	Aug 24	Option Exercise	177.82	10,037	1,784,779	104,452	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 24	Sale	593.63	20,037	11,894,577	84,415	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 21	Option Exercise	117.24	9,963	1,168,071	114,078	Aug 24 06:13 PM
SING GEORGE L	Director	Aug 21	Sale	605.12	19,963	12,080,040	94,415	Aug 24 06:13 PM
GOLDSTEIN JOSEPH L	Director	Aug 21	Sale	617.18	1,000	617,180	5,643	Aug 24 05:19 PM
SING GEORGE L	Director	Aug 20	Option Exercise	57.11	10,000	571,100	114,415	Aug 24 06:13 PM
Van Plew Daniel P	EVP & General Mgr Industrial O	Aug 20	Option Exercise	179.13	75,000	13,434,750	95,001	Aug 24 04:47 PM
McCourt Marion	SVP Commercial	Aug 20	Option Exercise	342.93	1,000	342,930	14,963	Oct 06 04:07 PM
McCourt Marion	SVP Commercial	Aug 20	Sale	612.15	1,000	612,150	13,963	Oct 06 04:07 PM
SING GEORGE L	Director	Aug 20	Sale	616.91	21,000	12,955,042	104,415	Aug 24 06:13 PM
VAGELOS P ROY	Director	Aug 11	Sale	602.94	33,460	20,174,355	50,192	Aug 13 04:02 PM
Landry Robert E	EVP Finance CFO	Aug 04	Sale	654.46	696	455,504	23,973	Aug 05 05:07 PM
RYAN ARTHUR F	Director	Aug 03	Sale	641.93	100	64,193	28,543	Aug 05 05:09 PM
Fenimore Christopher R.	VP Controller	Jul 21	Sale	642.04	3,709	2,381,317	17,501	Jul 22 04:31 PM
Landry Robert E	EVP Finance CFO	Jul 21	Sale	647.58	391	253,204	24,669	Jul 22 04:30 PM
Fenimore Christopher R.	VP Controller	Jul 20	Option Exercise	156.01	12,224	1,907,015	25,277	Jul 22 04:31 PM
Landry Robert E	EVP Finance CFO	Jul 20	Option Exercise	491.43	8,500	4,177,160	29,671	Jul 22 04:30 PM
MURPHY ANDREW J	EVP Research	Jul 14	Sale	633.48	2,380	1,507,677	41,951	Jul 15 04:51 PM
MURPHY ANDREW J	EVP Research	Jul 14	Sale	623.89	3,929	2,451,277	44,331	Jul 15 04:51 PM
Landry Robert E	EVP Finance CFO	Jul 14	Sale	640.50	579	370,850	23,973	Jul 14 04:17 PM
MURPHY ANDREW J	EVP Research	Jul 13	Option Exercise	30.63	13,000	398,190	54,951	Jul 15 04:51 PM
MURPHY ANDREW J	EVP Research	Jul 13	Sale	628.50	8,000	5,028,022	41,951	Jul 15 04:51 PM
Landry Robert E	EVP Finance CFO	Jul 09	Option Exercise	399.66	3,000	1,198,980	26,973	Jul 13 04:28 PM
Landry Robert E	EVP Finance CFO	Jul 08	Sale	639.66	1,160	742,011	23,973	Jul 09 04:29 PM
SING GEORGE L	Director	Jul 07	Option Exercise	33.42	7,500	250,650	122,915	Jul 08 04:16 PM
Landry Robert E	EVP Finance CFO	Jul 07	Option Exercise	524.47	12,500	6,555,850	33,973	Jul 09 04:29 PM
Zoghbi Huda Y	Director	Jul 07	Option Exercise	391.92	1,706	668,616	2,349	Jul 08 04:14 PM
SING GEORGE L	Director	Jul 07	Sale	650.16	3,000	1,950,474	400	Jul 08 04:16 PM
SING GEORGE L	Director	Jul 07	Sale	650.00	7,500	4,875,000	115,415	Jul 08 04:16 PM
Zoghbi Huda Y	Director	Jul 07	Sale	650.00	1,706	1,108,900	643	Jul 08 04:14 PM
BROWN MICHAEL S	Director	Jul 01	Option Exercise	413.33	3,613	1,493,361	4,256	Jul 02 04:02 PM
RYAN ARTHUR F	Director	Jul 01	Sale	609.70	100	60,970	28,643	Jul 02 04:01 PM
BROWN MICHAEL S	Director	Jul 01	Sale	607.62	3,613	2,195,342	643	Jul 02 04:02 PM
Landry Robert E	EVP Finance CFO	Jun 29	Sale	612.57	400	245,029	23,973	Jun 30 04:02 PM
SING GEORGE L	Director	Jun 29	Sale	608.91	3,000	1,826,721	1,400	Jun 29 04:08 PM
Landry Robert E	EVP Finance CFO	Jun 23	Sale	631.27	512	323,212	24,373	Jun 24 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 22	Option Exercise	555.67	8,900	4,945,463	33,273	Jun 24 04:03 PM
Bassler Bonnie L	Director	Jun 19	Option Exercise	391.92	2,559	1,002,923	3,202	Jun 22 04:18 PM
Bassler Bonnie L	Director	Jun 19	Sale	630.02	2,559	1,612,211	643	Jun 22 04:18 PM
Fenimore Christopher R.	VP Controller	Jun 16	Sale	590.89	3,556	2,101,215	15,277	Jun 17 04:02 PM
Fenimore Christopher R.	VP Controller	Jun 15	Option Exercise	47.07	9,406	442,742	20,323	Jun 17 04:02 PM
Zoghbi Huda Y	Director	Jun 11	Option Exercise	391.92	1,706	668,616	2,349	Jun 12 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 11	Sale	612.08	988	604,731	24,373	Jun 12 04:01 PM
Zoghbi Huda Y	Director	Jun 11	Sale	625.00	1,706	1,066,250	643	Jun 12 04:03 PM
Zoghbi Huda Y	Director	Jun 10	Option Exercise	391.92	1,706	668,616	2,349	Jun 12 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 10	Option Exercise	272.70	3,500	954,450	27,873	Jun 12 04:01 PM
Zoghbi Huda Y	Director	Jun 10	Sale	610.24	1,706	1,041,068	643	Jun 12 04:03 PM
Landry Robert E	EVP Finance CFO	Jun 09	Sale	608.01	4,271	2,596,792	24,373	Jun 10 04:04 PM
GOLDSTEIN JOSEPH L	Director	Jun 08	Option Exercise	413.33	10,838	4,479,671	17,481	Jun 09 04:05 PM
Landry Robert E	EVP Finance CFO	Jun 08	Option Exercise	272.70	15,500	4,226,850	29,860	Jun 10 04:04 PM
GOLDSTEIN JOSEPH L	Director	Jun 08	Sale	592.95	10,838	6,426,362	6,643	Jun 09 04:05 PM
Bassler Bonnie L	Director	Jun 05	Option Exercise	391.92	2,559	1,002,923	3,202	Jun 05 04:15 PM
Bassler Bonnie L	Director	Jun 05	Sale	600.00	2,559	1,535,400	643	Jun 05 04:15 PM
RYAN ARTHUR F	Director	Jun 01	Sale	603.23	100	60,323	28,743	Jun 02 04:04 PM
SING GEORGE L	Director	May 29	Sale	596.51	1,000	596,510	2,400	Jun 01 04:08 PM
SING GEORGE L	Director	May 28	Sale	579.00	1,000	579,000	2,900	Jun 01 04:08 PM
GOLDSTEIN JOSEPH L	Director	May 28	Sale	578.94	1,000	578,940	6,643	Jun 01 04:02 PM
VAGELOS P ROY	Chairman of the Board	May 21	Sale	577.49	783	452,178	307,749	May 22 06:21 PM
VAGELOS P ROY	Chairman of the Board	May 21	Sale	564.37	148,811	83,984,786	308,532	May 22 06:21 PM
VAGELOS P ROY	Chairman of the Board	May 20	Option Exercise	30.63	312,500	9,571,875	497,063	May 22 06:21 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 15	Sale	572.00	8,380	4,793,360	14,438	May 15 04:03 PM
LAROSA JOSEPH J	EVP General Counsel and Secret	May 14	Option Exercise	59.20	18,311	1,084,011	32,749	May 15 04:03 PM
SING GEORGE L	Director	May 13	Option Exercise	33.42	5,000	167,100	120,415	May 13 09:00 PM
SING GEORGE L	Director	May 13	Sale	580.00	5,000	2,900,000	115,415	May 13 09:00 PM
SCHLEIFER LEONARD S	President & CEO	May 12	Sale	569.22	150,922	85,908,042	474,499	May 13 09:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience